The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing
Open accessAbstract
Proton pump inhibitors (PPIs) are widely used for acid suppression in the treatment and prevention of many conditions, including gastroesophageal reflux disease, gastric and duodenal ulcers, erosive esophagitis, Helicobacter pylori infection, and pathological hypersecretory conditions. Most PPIs are metabolized primarily by cytochrome P450 2C19 (CYP2C19) into inactive metabolites, and CYP2C19 genotype has been linked to PPI exposure, efficacy, and adverse effects. We summarize the evidence from the literature and provide therapeutic recommendations for PPI prescribing based on CYP2C19 genotype (updates at www.cpicpgx.org). The potential benefits of using CYP2C19 genotype data to guide PPI therapy include (i) identifying patients with genotypes predictive of lower plasma exposure and prescribing them a higher dose that will increase the likelihood of efficacy, and (ii) identifying patients on chronic therapy with genotypes predictive of higher plasma exposure and prescribing them a decreased dose to minimize the risk of toxicity that is associated with long‐term PPI use, particularly at higher plasma concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Self-citationSIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Pharmacology of proton pump inhibitors
Shin, J. M., & Sachs, G. (2008) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0098-4 · Cited by 538
Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., Hanai, H., Kubota, T., Ishizaki, T., & Kaneko, E. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00006 · Cited by 335
Self-citationgenotype status and effect of omeprazole on intragastric pH in humans
FURUTA, T., OHASHI, K., KOSUGE, K., ZHAO, X., TAKASHIMA, M., KIMURA, M., NISHIMOTO, M., HANAI, H., KANEKO, E., & ISHIZAKI, T. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70075-5 · Cited by 272
Self-citationProton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
El Rouby, N., Lima, J. J., & Johnson, J. A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1461835 · Cited by 263
Self-citationThe risks of long-term use of proton pump inhibitors: a critical review
Jaynes, M., & Kumar, A. B. (2019) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618809927 · Cited by 254
Pharmacogenomics-based Tailored Versus Standard Therapeutic Regimen for Eradication of H. pylori
Furuta, T., Shirai, N., Kodaira, M., Sugimoto, M., Nogaki, A., Kuriyama, S., Iwaizumi, M., Yamade, M., Terakawa, I., Ohashi, K., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100043 · Cited by 187
Self-citationChang, M., Tybring, G., Dahl, M., Gotharson, E., Sagar, M., Seensalu, R., & Bertilsson, L. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04488.x · Cited by 184
Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients
Kurzawski, M., Gawronska-Szklarz, B., Wrześniewska, J., Siuda, A., Starzyñska, T., & Droździk, M. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0183-2 · Cited by 106
Hassan‐Alin, M., Andersson, T., Niazi, M., & R�hss, K. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0841-1 · Cited by 92
Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19
Kim, K., Shon, J., Park, J. Y., Yoon, Y., Kim, M., Yun, D., Kim, M., Cha, I., Hyun, M. H., & Shin, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126176 · Cited by 70
Tanaka, Μ. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113723 · Cited by 63
Mougey, E. B., Williams, A., Coyne, A. J. K., Gutiérrez‐Junquera, C., Fernández‐Fernández, S., Cilleruelo, M. L., Rayo, A., Echeverría, L., Román, E., González‐Lois, C., et al. (2019) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002480 · Cited by 55
Self-citationCYP2C19 Phenotype and Risk of Proton Pump Inhibitor–Associated Infections
Bernal, C. J., Aka, I. T., Carroll, R. J., Coco, J., Lima, J. J., Acra, S. A., Roden, D. M., & Driest, S. L. V. (2019) · PEDIATRICS · doi:10.1542/peds.2019-0857 · Cited by 39
Self-citationEffects ofCYP2C19Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers
Park, S., Hyun, Y. J., Kim, Y. R., et al. (2017) · Journal of Korean Medical Science · doi:10.3346/jkms.2017.32.5.729 · Cited by 35
Franciosi, J. P., Mougey, E. B., Williams, A., Gomez‐Suarez, R. A., Thomas, C. D., Creech, C. L., George, K., Corao, D., & Lima, J. J. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.977 · Cited by 34
Self-citationCicali, E. J., Blake, K., Gong, Y., Mougey, E. B., Al‐Atrash, H., Chambers, N. K., Denham, J. M., Evans, J., George, D. E., Gomez, R., et al. (2018) · Clinical and Translational Science · doi:10.1111/cts.12589 · Cited by 34
Self-citationShimatani, T., Inoue, M., Kuroiwa, T., Horikawa, Y., Mieno, H., & Nakamura, M. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01804.x · Cited by 32
Structural variation at the CYP2C locus: Characterization of deletion and duplication alleles
Botton, M. R., Lu, X., Zhao, G., Repnikova, E. A., Seki, Y., Gaedigk, A., Schadt, E. E., Edelmann, L. J., & Scott, S. A. (2019) · Human Mutation · doi:10.1002/humu.23855 · Cited by 26
Self-citationInhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent
He, N., Huang, S., Zhu, R., Tan, Z., Liu, J., Zhu, B. Y., & Zhou, H. (2003) · Xenobiotica · doi:10.1080/0049825021000023996 · Cited by 24
On behalf of the Best Pharmaceuticals for Children Act–Pediatric Trials Network, Shakhnovich, V., Smith, P. B., Guptill, J. T., James, L. P., Collier, D. N., Wu, H., Livingston, C. E., Zhao, J. M., Kearns, G. L., et al. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0305-1 · Cited by 22
Self-citationTang, M. C., Blake, K., Lima, J. J., Mougey, E. B., Franciosi, J. P., Schmidt, S., Hossain, J., Cobbaert, M., Fischer, B. M., & Lang, J. E. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.01.009 · Cited by 17
Self-citation
Cited by
Malfertheiner, P., Camargo, M. C., El-Omar, E., Liou, J.-M., Peek, R., Schulz, C., Smith, S. I., & Suerbaum, S. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00431-8 · Cited by 1,191
Cytochrome P450 Enzymes and Drug Metabolism in Humans
Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312808 · Cited by 1,070
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
Chey, W. D., Howden, C. W., Moss, S. F., Morgan, D. R., Greer, K. B., Grover, S., & Shah, S. C. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002968 · Cited by 419
Pharmacogenomics: current status and future perspectives
Pirmohamed, M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00572-8 · Cited by 351
Metadata
- Authors
- Lima, J. J., Thomas, C. D., Barbarino, J., Desta, Z., Van Driest, S. L., El Rouby, N., Johnson, J. A., Cavallari, L. H., Shakhnovich, V., Thacker, D. L., Scott, S. A., Schwab, M., Uppugunduri, C. R. S., Formea, C. M., Franciosi, J. P., Sangkuhl, K., Gaedigk, A., Klein, T. E., Gammal, R. S., & Furuta, T.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2020-09-20
- Volume
- 109
- Issue
- 6
- Pages
- 1417-1423
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W3047884069
- Cited by
- 315
- References
- 23
- FWCI
- 31.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.